We serve N,N-Diethyl-3-(trimethoxysilyl)propan-1-amine CAS:41051-80-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N,N-Diethyl-3-(trimethoxysilyl)propan-1-amine
CAS.NO:41051-80-3
Synonyms:N,N-diethyl-3-trimethoxysilylpropan-1-amine; N,N-Diethyl-3-(trimethoxysilyl)propylamine; [3-(Diethylamino)propyl]trimethoxysilane; (N,N-Diethyl-3-aminopropyl)trimethoxysilane;
Molecular Formula:C10H25NO3Si
Molecular Weight:235.39600
Physical and Chemical Properties:
Density:0.95;
Boiling point:120oC;
Flash point:100oC;
Index of Refraction:1.423;
Specification:
Appearance:Yellowish clear liquid with amine odor
Purity(GC):≥98.0%
Packing:180 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:It can be used as coupling agent, adhesion promoters, surface modifier etc.
Contact us for information like N,N-Diethyl-3-(trimethoxysilyl)propan-1-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(N,N-Diethyl-3-aminopropyl)trimethoxysilane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(N,N-Diethyl-3-aminopropyl)trimethoxysilane Use and application,N,N-diethyl-3-trimethoxysilylpropan-1-amine technical grade,usp/ep/jp grade.
Related News: API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.4-propan-2-yl-1,3-thiazole-2-carboxylic acid manufacturer API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.1-(bromomethyl)-4-fluoro-2-(trifluoromethyl)benzene supplier API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine.p-toluidine vendor The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers.The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers.
